特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
949415

鎌状赤血球病治療の世界市場:2019-2025年

Sickle Cell Disease Treatment Market 2019-2025

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.40円
鎌状赤血球病治療の世界市場:2019-2025年
出版日: 2020年05月15日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の鎌状赤血球病治療市場は、予測期間中、大幅なCAGRで成長すると見込まれています。市場の成長を促進する主な要因には、医薬品企業によるイノベーションの高まりおよび各国政府のサポートが含まれます。

当レポートでは、世界の鎌状赤血球病治療市場について調査分析し、市場概要、市場成長への影響要因、市場規模と予測、セグメント別の市場分析、地域・国別の市場分析、競合情勢などについて、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要および考察

  • 調査範囲
  • アナリストの考察&現在の市場動向
  • 規則&規制

第3章 競合情勢

  • 企業シェア分析
  • 主要戦略分析
  • 主要企業分析
    • Emmaus Life Science, Inc.
    • Bristol-Myers Squibb Co.
    • Pfizer, Inc.
    • Global Blood Therapeutics, Inc
    • Novartis AG

第4章 市場決定要因

  • 促進要因
  • 抑制要因
  • 機会

第5章 市場セグメンテーション

  • 世界の鎌状赤血球病治療市場:タイプ別
    • 投薬
    • 輸血
    • 骨髄移植
  • 世界の鎌状赤血球病治療市場:疾病タイプ別
    • 鎌状赤血球貧血
    • 鎌状ヘモグロビンC病
    • 鎌状ベータサラセミア
    • 鎌状ベータゼロサラセミア

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • その他アジア太平洋地域
  • その他の地域

第7章 企業プロファイル

  • Acceleron Pharma, Inc.
  • Arena Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Baxter International, Inc.
  • Blue bird bio, Inc.
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Emmaus Life Science, Inc.
  • Global Blood Therapeutics, Inc.
  • Medunik USA, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi S.A.
図表

LIST OF TABLES

  • 1. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
  • 2. GLOBAL MEDICATION MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 3. GLOBAL BLOOD TRANSFUSIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 4. GLOBAL BONE-MARROW TRANSPLANT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
  • 6. GLOBAL SICKLE CELL ANEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 7. GLOBAL SICKLE HEMOGLOBIN C DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 8. GLOBAL SICKLE BETA THALASSEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 9. GLOBAL SICKLE BETA-ZERO THALASSEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 10. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 11. NORTH AMERICAN SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 12. NORTH AMERICAN SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BYTYPE, 2018-2025 ($ MILLION)
  • 13. NORTH AMERICAN SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
  • 14. EUROPEAN SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 15. EUROPEAN SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
  • 16. EUROPEAN SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
  • 17. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 18. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
  • 19. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
  • 20. REST OF THE WORLD SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BYTYPE, 2018-2025 ($ MILLION)
  • 21. REST OF THE WORLD SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SHARE BY TYPE, 2018 VS 2025 (%)
  • 2. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SHARE BY DISEASE TYPE, 2018 VS 2025 (%)
  • 3. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 4. US SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. UK SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. SPAIN SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. ROE SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 16. REST OF THE WORLD SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
目次
Product Code: OMR2021734

Sickle Cell Disease Treatment Market Size, Share & Trends Analysis Report, by Type (Medication (Hydroxyurea, L-Glutamine Oral Powder, Crizanlizumab, Voxelotor, Pain-relieving Medication, and others), Blood Transfusions and Bone-Marrow Transplant), by Disease Type (Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta-Thalassemia, and Sickle Beta-Zero Thalassemia), and Forecast 2019-2025

The global sickle cell disease treatment market is estimated to grow significantly during the forecast period. The major factors encouraging market growth include includes growing innovation by the pharmaceutical companies and the support of governments of various countries. For instance, in November 2019, the US FDA announced the approval of Adakveo (Crizanlizumab-tmca) treatment with the aim to reduce the frequency of vaso-occlusive crisis in the sickle cell disease patients of age 16 year and above. In November 2019, FDA approved the use of Voxelotor (Oxbryta) for sickle cell disease treatment. Voxelotor is a polymerization inhibitor used to reduce the concentration of deoxygenated sickle hemoglobin helping in stopping the formation of polymer in red blood cells.

The growing number of sickle cell anemia disease owing to the increase in demand for sickle cell anemia treatment encouraging the sickle cell disease treatment market to grow. Sickle cell anemia is a disorder in which the red blood cell unable to transport a significant amount of oxygen to the organs. In this condition, the red blood cell becomes rigid, sticky and sickle in shape resulting in blockages of oxygen through red blood cells. The growing initiatives by the government toward sickle cell anemia treatment encouraging major companies in the innovation of multiple treatment options. This in turn supporting the growth of the market.

The global sickle cell disease treatmentmarket is segmented based on type and disease type. Based on drug type, the market is classified into medication, blood transfusions, and a bone-marrow transplant. Based on disease type, the market is classified into sickle cell anemia, sickle hemoglobin c disease, sickle beta-thalassemia and sickle beta-zero thalassemia.Geographically, the global sickle cell disease treatment market is classified into North America, Europe, Asia-Pacific and the Rest of the World.

The major players in the global sickle cell disease treatment market include Emmaus Life Science, Inc., Bristol-Myers Squibb Co., Pfizer, Inc., Global Blood Therapeutics, Inc., and Novartis AG. The strategies followed by the market players include mergers and acquisitions, partnerships and collaborations and geographical expansion to expand market share across the globe.For instance, in November 2016, Novartis AG announced its acquisition of Selexys Pharmaceuticals and the SelG1 antibody with the aim of reduced pain treatment for sickle cell disease patients in adults. This acquisition will strengthen Novartis's product portfolio of sickle cell disease treatment.

Research Methodology

The market study of the global sickle cell disease treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Authentic public databases
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for drug manufacturers, suppliers and distributors, and government agenciesfor overall market analysis and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

  • Global Sickle Cell Disease TreatmentMarket Research and Analysis by Type
  • Global Sickle Cell Disease TreatmentMarket Research and Analysis by Disease Type

The Report Covers:

  • Comprehensive research methodologies of the global sickle cell disease treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global sickle cell disease treatment market.
  • Insights about market determinants which are stimulating the global sickle cell disease treatmentmarket.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Emmaus Life Science, Inc.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Bristol-Myers Squibb Co.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Pfizer, Inc.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Global Blood Therapeutics, Inc
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Novartis AG
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Sickle Cell Disease Treatment Market by Type
    • 5.1.1. Medication
      • 5.1.1.1. Hydroxyurea
      • 5.1.1.2. L-Glutamine Oral Powder
      • 5.1.1.3. Crizanlizumab
      • 5.1.1.4. Pain-Relieving Medications
      • 5.1.1.5. Voxelotor
    • 5.1.2. Blood Transfusions
    • 5.1.3. Bone-Marrow Transplant
  • 5.2. Global Sickle Cell Disease Market by Disease Type
    • 5.2.1. Sickle Cell Anemia
    • 5.2.2. Sickle Hemoglobin C Disease
    • 5.2.3. Sickle Beta Thalassemia
    • 5.2.4. Sickle Beta-Zero Thalassemia

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Acceleron Pharma, Inc.
  • 7.2. Arena Pharmaceuticals, Inc.
  • 7.3. AstraZeneca plc
  • 7.4. Baxter International, Inc.
  • 7.5. Blue bird bio, Inc.
  • 7.6. Bristol-Myers Squibb Co.
  • 7.7. Eli Lilly and Co.
  • 7.8. Emmaus Life Science, Inc.
  • 7.9. Global Blood Therapeutics, Inc.
  • 7.10. Medunik USA, Inc.
  • 7.11. Novartis AG
  • 7.12. Pfizer, Inc.
  • 7.13. Sangamo Therapeutics, Inc.
  • 7.14. Sanofi S.A.
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.